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1.Introduction to N-ECCO Statements 
This is the second Nurse European Crohns and Colitis (N-ECCO) consensus statements document 
addressing inflammatory bowel disease (IBD) nursing across Europe. N-ECCO continues to be an 
active member of European Crohns and Colitis Organisation (ECCO), providing education and 
networking opportunities for nurses across Europe within three designated nurse sessions, N-ECCO 
Network Meeting, N-ECCO School and the N-ECCO Research Forum, in addition to e-learning and 
podcasts.  
1.1 Aim 
The over-arching aim of ECCO is to improve the care of patients with IBD through the development 
of guidelines, education and research. Current evidence is fundamental to enable N-ECCO to meet 
this progressive aim. This document updates the first N-ECCO consensus statements based on the 
‘ideal’ standard of care [1], and provides additional statements and evidence supporting 
contemporary IBD nursing practice, whilst acknowledging the extensive variety in IBD nursing 
practice across Europe [2]. 
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1.2 Methods and results 
 
The N-ECCO consensus statements required revision due to the emergence of new evidence 
supporting the role of the IBD nurse. In line with Standard Operating Procedures set out by ECCO, 
the proposal to update the statements was approved by ECCO’s Governing Board. The ECCO Office 
sent an international call for N-ECCO members in January 2017; ten nurses and the current N-ECCO 
committee of 2017 were selected and divided into four working groups (WG) in March 2017, each 
responsible for a different section of the consensus document. 
 
Each WG performed literature searches to enable review of original statements and to add new 
statements. The electronic literature search databases included AGRIS, Embase, Global health, 
HMIC, Journals @ Ovid full-text, OVID Medline (R) In-process Non-indexed citations, and Medline, 
PsychArticles Full text, PsychInfo, Your Journals @ OVID EMBASE, CINAHL and the British Nursing 
Index via the OVID platform from 2010 onwards. 
The consensus process was based on a modified Delphi method, a recommended method to 
determine consensus for a defined clinical concern [3, 4]. The iterative method uses rounds of voting 
to determine consensus of opinion [4] with participants debating the agreed statements at the final 
voting round [5]. The updated statements document was submitted to an online platform for 
discussion and for online voting by all national representatives of N-ECCO in May 2017.  63% of 
national representatives and the consensus working group voted. 83% of the statements gained over 
90% consensus suggesting further online consensus rounds were unnecessary. Statements receiving 
less than 80% consensus were reviewed and for the second and final voting round, which took place 
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in June 2017, the consensus working group met and achieved 100% consensus agreement for all 31 
statements.  
  
The consensus statements are divided into four sections. ‘Fundamental IBD Nursing’ details the basic 
nursing care required to meet the needs of patients with IBD, delivered by nurses working across 
many settings. The section ‘Advanced IBD Nursing’ pertains to nurses who have developed their 
knowledge, skills, research and expertise in IBD. ‘Advanced IBD nursing care for particular situations’ 
provides guidance on supporting patients with IBD facing special situations, and ‘Benefit of an IBD 
Nurse’, addresses the value and benefits of the specialist nurse within the IBD multidisciplinary 
team.  
 
2. Fundamental Inflammatory Bowel Disease (IBD) Nursing  
 
 
N-ECCO Statement 2A 
Nurses in contact with patients with IBD working in any setting need basic knowledge of the 
diseases,  to know the difference between Crohn’s disease and ulcerative colitis, and to appreciate 
the importance of establishing timely therapeutic interventions. Understanding of key diagnostic 
strategies and the main medical and surgical options available in the management of IBD is 
recommended [EL2]  
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IBD is an umbrella term for the life-long bowel diseases of ulcerative colitis (UC) and Crohn’s 
disease (CD). IBD is a global disease with a rising prevalence [6, 7] which follows an unpredictable 
relapsing and remitting course. Common symptoms of active disease in both conditions include 
diarrhoea, abdominal pain, anaemia and fatigue.  
 
Although the causes of IBD are unknown, it is recognised as an immune-mediated disease, 
possibly precipitated by various genetic and environmental factors, it is advisable to read the ECCO 
Topical review on environmental factors in IBD [8]. Although IBD often presents in adolescence or 
young adulthood, 10 – 30% of patients are over 60 years old, either having aged with IBD or 
developed it in middle adulthood. Illness in older adults is often complicated by physical changes of 
ageing, associated co morbidities and atypical presentations [9]. Paediatric forms of IBD are 
characterised by a more complicated disease course with marked inflammatory activity and frequent 
need for corticosteroids and immunosuppressive therapy compared with adult-onset IBD [10].  
 
UC affects only the rectum and colon. Originating in the rectum, it can extend proximally to the 
sigmoid, descending, or entire colon [11]. The inflammation is continuous and limited to the mucosa. 
Symptoms include rectal bleeding, passing mucus, abdominal pain, diarrhoea and faecal urgency, 
sometimes with incontinence. Location and severity of disease activity determines therapy options 
[12].  
 
CD occurs anywhere between mouth and anus. The inflammation is intermittent, with 
patches of disease activity (skip lesions) between areas of healthy mucosa. Symptoms vary according 
to disease location and include abdominal pain, diarrhoea, weight loss, anorexia and fever. Nausea 
2.1 Definition and requirements  
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and vomiting can occur if strictures cause intestinal obstruction [13]. Initially an inflammatory 
process, CD can progress to a stenosing / stricturing or penetrating / fistulising pattern, each adding 
considerably to disease burden, with a reported occurrence of perianal fistulae to be between 21% 
and 23% in population based studies [14]. 
 
Patients may develop extra intestinal manifestations (EIMs) with up to 50% of patients with 
IBD experiencing at least one EIM which may present before diagnosis and can affect joints, skin, 
eyes and liver [15]. Patients with IBD are at increased risk of developing colorectal cancer (CRC); in 
both UC and CD, the risk varies with the extent and duration of disease, family history of CRC, and 
presence/absence of primary sclerosing cholangitis (PSC). Over the past 35 years, risk of CRC in 
patients with IBD has not declined significantly, but risk of dyi g from CRC has decreased [16]. 
 
2.2 IBD Diagnosis and treatments  
Diagnosis is confirmed by clinical evaluation (patient history, physical assessment) and a 
combination of endoscopic, histological, radiological, and/or biochemical investigations [13]. 
Inflammatory markers, such as faecal calprotectin, may also be used [17]. Endoscopy with biopsy of 
the colon and terminal ileum may confirm diagnosis. Computed tomography (CT) and magnetic 
resonance imaging (MRI) scans enable evaluation of disease extent, activity and complications [12, 
13]. A working knowledge of diagnostic procedures enables all nurses to support patients with their 
questions and during preparation for investigations.   
Medical treatments aim to induce and maintain remission, and improve health-related 
quality of life (HRQoL). The complex choice of single or combined drug therapy is influenced by 
location and severity of disease, treatment availability, local experience,  individual patient 
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circumstances such as tolerance, side-effects, drug interactions, pregnancy, and patient and clinician 
preference. Detailed explanations of recommended medical treatments are available in current 
ECCO consensus documents [12, 13]. 
 
Approximately 30% of patients with UC and up to 70% of patients with CD will require 
surgery at least once in their lives [18, 19]. Surgery for CD may include small bowel resections, 
subtotal colectomy, temporary ileostomy, ileo-rectal anastomosis, or pan-proctocolectomy [20]. 
Iloecaecal resection is sometimes indicated for isolated terminal ileal disease, and surgery and 
endoscopy procedures may be necessary to treat strictures and fistulae. Surgical interventions for 
UC include restorative proctocolectomy with ileal-pouch anal anastomosis, subtotal colectomy with 
end-ileostomy and subtotal colectomy with ileorectal anastamosis[21]. Pouch surgery and pouch 
dysfunction is covered in section 4 ‘Advanced IBD nursing care for particular situations. Surgery may 
improve HRQoL in patients with CD and relieves patients with UC of unremitting inflammation, 
although EIMs can remain [22]. A consistent patient-reported fear is the potential need for a stoma 
[23-26], although stoma-forming surgery may have significant benefits for HRQoL [27-29]. 
IBD can have significant negative impact on patients’ HRQoL; prolonged disease activity,  
disease complications, the uncertain nature of IBD, and risk of developing cancer cause particular 
concern [30, 31]. Alongside objective measures of disease such as endoscopy results, patient 
reported outcome measures (PROMs) are emerging as a means of gauging the impact of these 
concerns, and the effectiveness of interventions [32-34]. PROMs developed with patient and 
clinician input more accurately reflect the concerns of each and will become an important future 
aspect of assessing disease activity and licensing IBD-specific drugs [32-34] 
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Timely therapeutic intervention is essential for disease control [35]. Nurses with a basic 
knowledge of IBD are advised to consult the Advanced IBD Nurse or gastroenterologist where 
appropriate, according to local referral procedures. 
 
2.3 Impact of IBD on patients’ lives 
 
N-ECCO Statement 2B 
Nurses caring for patients with IBD need an awareness of the immediate and long term physical, 
social and emotional impact of the disease including patients' key concerns, and the effect of IBD on 
Health-Related Quality of Life [EL3] 
 
A major life impact is the need to be near a toilet. Urgency can be severe, with some 
patients reporting less than 30 seconds between calls to stool and actual defecations [36]. Fear of 
losing bowel control is so great that some patients always worry about where the nearest toilet is 
[31, 36, 37]. Recent evidence suggests that, at some point of the disease course, between 31 and 
74% of people with IBD experience faecal incontinence [36, 38, 39], not necessarily related to 
disease activity [37]. Despite it being a major concern, incontinence is rarely reported to or 
addressed by clinicians. 
 
IBD can have an immediate and lifelong psychological impact [40]. Nurses can provide support and 
help patients utilise appropriate tools to facilitate self-management. The immediate impact results 
from embarrassment, hospitalisation, fears and concerns about the uncertain origin and course of 
disease [41] and possibility of cancer [41, 42]. Concerns about possibly requiring surgery and / or a 
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stoma bag, body image, loss of bowel control, and producing unpleasant odours are particularly 
distressing [43]. During hospitalisation, bowel control difficulties are more likely, due to relapse and 
shared toilet facilities with limited availability. Nurses can provide empathetic support and may be 
able to influence easier access to facilities. Discreet assistance and maintenance of patient dignity in 
the event of incontinence is essential. 
Lifestyle impacts of IBD include self-imposed or professionally recommended dietary 
restrictions to control symptoms and long term medication to control disease, with patients 
constantly monitoring behaviors that may trigger symptoms [41]. There can be an ambivalent 
relationship with eating, including food-avoidance due to concerns about potential after- effects 
[44].  
Impact on daily activities may include absence from school or work, and difficulties meeting 
employment requirements. Patients may feel stressed about taking time off work due to IBD and 
40% make adjustments such as working from home, working shorter days or working part time [30]. 
Research suggests fatigue is the commonest reason for absence, with patients reporting insufficient 
energy to last through the full working day [30].        
 
 As IBD is unpredictable, patients may have difficulty planning or engaging in activities, both of which 
are often influen ed by toilet access and availability [41]. Social and leisure activities are negatively 
affected when patients have to avoid, make last minute changes to, or cancel planned activities due 
to symptoms [45].   
 
Although necessary, receiving IBD treatment may have a negative impact as it reminds 
patients about their illness. Concerns range from side effects of medication, inconvenience and 
burden of taking medication and financial burden. However, evidence suggests that strong social 
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support networks in patients with a chronic illness can facilitate effective coping, positively influence 
health status and improve outcomes of disease [46]. Family support, particularly that provided by 
parents, plays a vital role in the development of children and adolescents with IBD [47].  
 
2.4 Psychological impact of living with IBD 
N-ECCO Statement 2C 
Nurses caring for patients with IBD need to be aware of the psychological impact of IBD, including 
anxiety, depression and distress, and offer onward referral to appropriate specialist  support services 
if necessary (EL3) 
 
The unpredictability of IBD symptoms cause numerous physical and psychosocial challenges 
for patients [48], often independent of disease severity. IBD is a concealable illness, leading some to 
downplay the associated symptoms [45]. Many people feel stigmatized by IBD, often because it is a 
bowel disorder which others may perceive as dirty [49, 50], or by associated fatigue which others 
may misintepret as laziness [51]. Some patients report feeling damaged due to physical changes 
associated with IBD or treatments. Self-blame regarding onset of IBD can lead to poorer adjustment 
to disease and reduced HRQoL during remission and relapse. Even in remission, background 
persistent disease-related issues such as fatigue, EIMs and sleep difficulties can be detrimental for 
HRQoL [44, 52].  
 
One-fifth of patients experience depression, and one third experience anxiety [40]. Routine 
screening for signs of psychological morbidity is recommended, with referral to formal psychological 
counseling and support for those patients demonstrating higher levels of concern [40]. Screening 
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may be conducted using validated scales [53-57]. Interventions including cognitive behaviour 
therapy [57] and pharmacological agents such as selective serotonin re-uptake inhibitors may be 
beneficial. Mindfulness is a psychological skill linked to mental health and well-being encouraging 
the patient to be aware of moment-to-moment experiences and avoiding excessive, unnecessary 
upset [58]. Mindfulness interventions aim to develop skills to manage stress and have been shown 
to improve mood and quality of life, sustained at 6 months post intervention [58]. Psychotherapeutic 
interventions may be beneficial for patients with IBD who have co-existing IBS-type symptoms [59].   
 
Disease-related distress is a phenomena distinct from psychological morbidities such as 
anxiety, depression or stress and has been identified in other chronic diseases such as diabetes [60]. 
Disease-specific scales can be used to measure distress, ide tifying priority issues for patients and 
informing delivery of supportive interventions [61]. Nurses can also reduce disease-related distress 
by providing patients with realistic expectations about onset of therapeutic effects of medication 
and the transient nature of some side-effects, including temporary worsening of symptoms, weight 
gain and sexual dysfunction [57].    
 
 Some patients may struggle to disclose their diagnosis and symptoms to new potential partners, or 
find intimacy challenging due to sexual difficulties, fatigue and fear of incontinence [62]. Even if 
family members, partners and friends are usually supportive, there can be a lack of understanding 
[63]. Contact with other people with similar health problems may benefit patients [64]. Sharing 
experience with others who ‘know’ what it is like to have IBD, can provide important social, 
emotional and psychological support [65]. Nurses can provide contact details for country specific 
patient groups and charities. These fulfill an important supporting role for those dealing with a new 
diagnosis or with major developments of established disease. 
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  2.5. Patient Advocacy and Person-Centred Care 
N-ECCO Statement 2D 
 Nursing involves advocacy for all patients and this is of the utmost importance to patients with IBD 
due to the complex, uncertain and chronic nature of the condition. Advocacy can include identifying 
needs and ensuring appropriate access to the best care available [EL4] 
 
An advocate promotes and supports the interests of others [66]. Advocacy is universally considered 
a moral obligation in all clinical practice, particularly when the patient’s ability to make decisions, 
and to defend or protect themselves physically and emotionally, may be impaired due to illness [67-
69]. Examples of advocacy in practice include respecting patients’ rights, representing, speaking up 
for the patient’s point of view, protecting dignity and privacy [70]. Some interventions for IBD such 
as colonoscopy may be worrying to some individuals. Advocacy in this instance requires the nurse to 
understand the concerns, needs and preferences of the patient and assist the patient in meeting 
those needs or overcoming concerns to allow them to receive appropriate healthcare. Advocacy and 
appropriate support may include ensuring urgent and timely referral to Advanced IBD Nurses, 
gastroenterologists or stoma nurses [46], or assisting patients in voicing their concerns to the 
multidisciplinary team.    
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Nurses need to develop an empathetic and active listening role, and be able to provide essential IBD-
related information and holistic support [EL3]. Nurses have a role in facilitating communication 
between the multidisciplinary team and the patient, enabling shared decision-making [EL3]  
 Verbal and non-verbal communication is vital in nursing; it helps meet patients’ needs, and enables 
provision of support, advice, compassion, caring and empathy that is highly valued by patients [46, 
71, 72]. Virtual contact with IBD nurses via telephone and email clinics is recommended, enabling a 
more flexible and patient-focussed approach to management [73]. Age-appropriate support should 
be offered by those who are best placed to meet the needs of patients and their family members or 
carers [74].  
 
In any chronic illness where the individual will have an ongoing relationship with health care 
professionals, communication facilitates rapport and trust [75]. The resulting therapeutic nurse-
patient relationship can encourage the patient to have an active rather than passive role in their 
care, and to recognise their expertise about their own illness [76-78].  
 
Nurses should be empathetic, active listeners with sufficient knowledge to give basic guidance on 
key areas of concern for patients. This may include diet, social problems, aetiology of IBD, 
common symptoms and complications, medication and related potential side effects, and 
surgical treatments [79, 80]. Patients value the opportunity to be listened to and ‘taken seriously.’ 
However the nurse should not advise beyond their competency [81], and refer the patient to 
another healthcare professional within the the IBD-MDT where appropriate. 
 
N-ECCO Statement 2E 
2.6. Communicating with the patient with IBD 
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Patients with IBD may struggle at various stages of their disease with the loss of their 
healthy self [82]. This can affect the way the newly-diagnosed individual gives, seeks, 
receives and processes information. Worries and physical symptoms can also affect the 
ability to process information and the nurse must share this in a way that it cannot be 
misinterpreted [83]. Reliable printed information leaflets or web-based materials are 
recommended to supplement verbal information [79, 84, 85].  
 
The method and source of information may need adjusting to meet individual patient 
requests [80]. Patients may forget up to 50% of medication information provided, mostly 
recalling medication intake aspects. Techniques such as summarising, categorising, and 
supplementing consultations with written information may improve patients’ medication 
knowledge and recall [86]. Patients who participate in their care and share decision-making 
have appreciably better outcomes than patients who do not [87]. Similarly, patients who 
understand the benefits and risks of a disease management plan are more likely to accept it, and be 
more willing to share in and follow their treatment and monitoring schedules [88].  
    
Effective communication between physicians, patients, and members of the MDT across 
different healthcare levels, is essential [73, 89]. The best care for patients is delivered within an IBD 
centre of excellence, founded on current consensus [88], and provided by a MDT with a named 
clinical lead [74]. An IBD-MDT could comprise specialist gastroenterologists, colorectal surgeons and 
nurses, dietician, pharmacist, pathologist and radiologist with special interest in gastroenterology 
[90].  
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Positive patient-clinician relationships, with good communication, are essential to optimize 
the quality of care, health outcomes, and patient satisfaction with healthcare in chronic diseases 
[91]. Person-centred care is one way of providing better care and support for people with IBD. In this 
approach, the individual and their family is at the centre of care management, the patient is 
recognised as an expert in their own health and enabling them to collaborate with healthcare 
professionals to achieve the best outcomes. The patient is treated as an active and responsible 
partner, and their narrative is listened to [92]. New concepts and practices include ‘patient 
participation’, ‘patient involvement’ and ‘patient engagement’, terms that are similar but should not 
be used interchangeably [93]. These concepts promote patient-empowerment which is recognised 
as being increasingly important in the management of chronic disease , and preferred by patients 
with IBD [94]. Shared decision-making is also beneficial, although data on factors influencing 
decision-making are limited [95].  
 
2.7 Fistulae 
 
N-ECCO Statement 2F 
In fistulising IBD, nurses have a role in ensuring patient comfort, protecting skin integrity, managing 
complications and educating the patient about fistulas. This can best be achieved by working in 
collaboration with the wider MDT including stoma care therapy, surgeon, gastroenterologist, and 
tissue viability team [EL5]. The potential psychological impacts should not be under-estimated [EL2] 
 
Fistulae may arise in CD as a communicating channel between the intestine and perianal 
skin, abdominal wall, or other organs [96, 97]. Five aspects are important for managing fistulae: i. 
identification or exclusion of local sepsis; ii. assessment of nutritional status; iii. location and 
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anatomy; iv. evaluation of the originating intestinal loop; v. determining organs affected by the 
fistula and their contribution to systemic systems or impairment of HRQoL [20, 98]. Diagnostic 
accuracy is achieved by multiple modalities [99].  
 
Fistulae management remains a major challenge in patient care, and has a significant impact 
on HRQoL [98]. Combined medical, surgical, nursing, nutritional, radiological and other specialist 
interventions may be required [100, 101]. Management of fistulae often requires referral to a 
specialist centre [102]. There is little evidence to inform nursing management of fistulising disease, 
but the nurse’s role may include wound care, medication administration, containment of sepsis, and 
support and close liaison with specialist wound care nurses and stoma care nurses to help enhance 
patient care and comfort [103]. 
 
Surgical interventions for perianal fistulae may include abscess drainage, seton placement, 
and fistulotomy. In severe cases, patients refractory to medical therapy may require a diverting 
stoma or proctectomy [104]. Nurses need to ensure patients are informed, signposting them to 
alternative sources of support where appropriate. Support could include enabling careful combined 
discussion between the patient, surgeon and specialist gastroenterologist. Referral to country 
specific patient support groups, provision of information leaflets and diagrams and, in specific 
situations, the consideration of referral for more formalised counseling to help the patient manage 
their symptoms and the impact on their daily living, may be beneficial [105]. 
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N-ECCO Statement 2G  
Nurses need knowledge of the potential nutritional issues in patients with IBD to ensure these are 
appropriately identified and managed [EL2]. Patients and carers may require ongoing support and 
education from nurses regarding nutrition and especially in specific situations such as stricturing 
disease, or following surgery. Referral to a specialist dietician is recommended [EL2]. Dietary 
interventions may have therapeutic benefit for patients with IBD [EL1] 
 
There is now an accepted link between Westernised diet and the incidence of IBD [8, 106, 
107]. Although causative mechanisms are still not yet fully understood, the combination of diet and 
genetic predisposition towards IBD may be influential and patients often enquire about links 
between diet and their IBD symptoms [107]. Patients are very interested in dietary modifications 
and often self-impose dietary restrictions, particularly of spicy, fatty and sugary foods, coffee, tea, 
carbonated drinks and alcohol, dairy products and vegetables [108]. However there is no evidence of 
the benefit of dietary restrictions. 
 
 Diet is also perceived to influence symptoms in CD more than in UC [109]. Patients with IBD need 
awareness of the importance of good nutrition to maintain maximum health, particularly as they 
may lose weight during relapse, or become deficient in nutrients including iron, vitamin D and 
calcium [110, 111]. Dietary advice is generally best provided by a dietician with special interest in 
IBD. Freely available dietary recommendations aimed at patients are highly conflicting and tend to 
focus on food restrictions [112].  
IBD nurses need to appreciate that there is no specific diet that works best for everyone 
with IBD [108] and the aim is to encourage patients to follow a normal healthy diet and lifestyle as 
tolerated. For some patients, diet may need to be tailored based on symptoms, preferences and 
 2.8 Diet and nutrition 
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needs [106, 113, 114] and some dietary interventions are beneficial in managing symptoms [115]. 
Nutrient supplements can improve nutritional status [116, 117] and exclusive enteral nutrition can 
induce and / or maintain remission in children and adults with IBD [118], either alone or in 
combination with medications [119].  
 
 
 2.9 Nutrient supplements, complementary and alternative medicines, and special diets 
 
Access to appropriate dietary assessment and specialist advice is important, as during the course of 
their illness some patients may experience general malnutrition or specific deficiencies of individual 
nutrients. Multiple factors can lead to nutritional problems impacting on health, nutritional status 
and HRQoL during active disease, although a wide range of nutritional and functional deficiencies 
can be evident after long periods of remission [120]. The most common nutritional deficiencies in 
IBD are macro-nutrients, vitamins such as B12 and D, folic acid, and minerals such as iron, calcium, 
magnesium, selenium, or zinc [110, 111, 121]. Deficiencies in serum albumin, vitamin D, vitamin B12, 
folate, and iron levels in patients with CD may indicate active inflammation [122].  
Vitamin D deficiency is high amongst patients with IBD, and may be due to sun-avoidance 
behaviours and reduced outdoor activity [123]. Lower levels of vitamin D  correlate with increased 
disease activity, but the causal relationship is not clear [124]. Vitamin D has an anti-inflammatory 
effect and supplementation improves outcomes [123, 125, 126], but the serum dose levels need 
ascertaining [124] and larger studies required in this area [127]. There is convincing evidence that 
only patients with CD who have an ileal resection greater than 20cms are predisposed to vitamin D 
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deficiency, warranting monitoring and treatment when necessary [128]. There is no evidence that 
supplements of the fat-soluble vitamins A, E and K are effective [126].  
 
The use of complementary or alternative medicines (CAM) is common across many patient 
populations and the most frequently-used CAMS are probiotics, multivitamins and supplements 
[129, 130]. Probiotics are used for pouchitis when preceded by antibiotic therapy [112]. Omega 3 
fatty acids are probably ineffective for maintaining remission in CD [131, 132]. There is insufficient 
evidence that glutamine, known to maintain the integrity of the intestinal mucosa and reduce 
inflammation in experimental models, is safe and effective in inducing remission in CD [133]. Aloe 
vera may be effective in active UC [134, 135], and curcumin can also be considered for induction 
therapy in mild to moderate UC [132].  
Special diets may or may not be effective. The low FODMAP diet has been consistently 
demonstrated to reduce functional GI symptoms (bloating, pain, gas) [136, 137]  and the nurse can 
refer to the specialist dietician if a low FODMAP diet is considered. 
 
2.10 Enteral nutrition as a therapy 
The impact of inadequate nutrition is more noticeable in the growing child or adolescent as 
nutritional deficiencies can lead to a risk of growth failure, delayed puberty, bone demineralisation 
or significant psychosocial complications [116, 117, 138]. In addition, nutrition is an integral part of 
paediatric IBD management. The first line treatment of choice for active paediatric CD is exclusive 
enteral nutrition therapy in which all of the patient’s requirements for energy, protein and other 
nutrients are met by a nutritionally complete liquid diet. This exclusive enteral nutrition (EEN) 
restores nutritional status and modulates intestinal immune responses [139]. It is an established 
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effective induction therapy for small and large bowel disease [118, 140], inducing response in 60 – 
80% of cases [118]. As first line treatment in children with active CD, EEN is an effective alternative 
to pharmacological treatment, helps reverse weight loss and growth failure, and may be better 
tolerated than steroids. Recent evidence suggests potential benefits of EEN for adults with CD [141, 
142], including inducing and maintaining remission, relieving bowel strictures and reducing post-
operative septic complications in fistulising disease [139, 142, 143]. Pre-operative EEN has been 
shown to reduce risks in urgent and planned surgery, and decrease the incidence of postoperative 
complications in patients with CD [144].  
 
 
 
 
2.11 Incontinence 
 
N-ECCO statement 2H 
Nurses need to recognise the impact of incontinence on Health Related Quality of Life. Management 
of faecal incontinence should be tailored to the needs of the individual. Formal referral to 
continence specialists for assessment and investigation may be appropriate [EL2]. Specific 
interventions such as pelvic floor exercises, evacuation techniques, dietary advice or information on 
continence products can be beneficial [EL1]  
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Faecal incontinence (FI) can be a significant problem for patients with IBD, affecting physical, 
psychological and social wellbeing and leading to symptoms of anxiety and depression [145]. 
Reported prevalence is between 24 - 74%, and risk factors include disease activity, vaginal delivery 
or previous IBD surgery [37-39, 146, 147]. There is a moderate risk of FI particularly at night in older 
patients or following ileo-anal anastomosis surgery [148]. Fear of incontinence is as debilitating as 
actual occurrence, and can leave patients housebound and unable to work [36]. 
 
Often patients find it difficult to reveal or discuss their bowel symptoms openly [149]. To properly 
address the issue of FI, the stigma surrounding it needs breaking down [36, 45, 150]. Simply by 
asking about symptoms, nurses can encourage patients to talk about continence issues [151]. Nurses 
have a vital role in helping patients to manage and improve the symptoms of FI. PROMs, such as the 
ICIQ-IBD [152] which incorporates the Bristol Stool chart [153] can facilitate accurate assessment of 
FI symptoms. Alongside provision of information and emotional support, specialist interventions for 
FI may include pelvic floor muscle exercises, perianal skin care, bowel retraining, anti-diarrhoeals, 
dietary management, behavioural therapy, and practical devices regarding anal plugs and pads. 
Optimisation of IBD treatments may also improve symptoms. There is also early evidence that 
electrical stimulation of the tibial nerve, a branches of the pudendal nerve supplying the pelvic floor, 
is beneficial [154]. However, all patients will not gain benefit from the same nursing intervention, 
therefore a tailored care plan should reflect each patient’s needs, taking lifestyle factors into 
account [155]. Specialist referral to local biofeedback or continence services, where appropriate, is 
recommended. 
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N-ECCO Statement 2I 
Issues relating to sexuality may cause anxiety, depression and concern for patients with IBD. Nurses 
identifying problems regarding sexual function and sexuality need to be able to support the patient 
and  refer to specialist services as appropriate [EL2] 
 
IBD commonly appears during young adulthood, and sexuality and self-confidence can be 
significantly affected. Sexual functioning is a marker for HRQoL, and IBD can have a meaningful 
impact on a person's body image, sexual functioning and interpersonal relationships [156-158]. High 
levels of sexual impairment have been identified amongst male and female patients with IBD [159, 
160], but sexual difficulties need to be identified to be  treated [62]. Emotional aspects may include 
concerns about body image, feeling unattractive, and worry about urgency and leakage of stool 
during intercourse. Unpredictability of the disease and fear of unexpected symptoms can lead to low 
self image or self esteem [161].  
 
Surgery may increase the negative impact of IBD in both males and females, particularly 
following proctectomy [162, 163]. Decreased libido affects patients with CD and UC equally [164] 
and female patients who have had surgery experience greater impairment of sexuality and sexual 
activity than males [165, 166]. 
  
The IBD nurse/patient relationship can foster the confidence for sexual concerns to be 
raised, signposting towards information and offering advice, to identifying the need for more 
structured support or specialist counseling. Tactful prompting and open discussion will identify the 
level of support needed [167]. No formal tools for measuring the impact of IBD on an individual's 
2.12 Sexuality and IBD  
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sexuality exist, but this may be beneficial in promoting an individualized approach to each situation 
[156]. 
Assisting gay, lesbian, bisexual and transgender (GLBT) patients solve problems associated 
with sexuality requires nurses to understand and feel comfortable discussing aspects of sexual 
practices of this patient group [168]. Nurses who feel under-informed can refer to the extensive 
literature on GLBT experiences within healthcare settings [169, 170]. The GLBT patient may not wish 
to publically receive emotional support from their partner during hospitalisation, and may therefore 
avoid hospital care. Gay and bisexual patients require precise information about sexual activity and 
restrictions [171].  
 
2.13 Pain management 
 
N-ECCO Statement 2J 
Nurses may be well placed to identify, acknowledge and provide treatment and support for 
patients with IBD experiencing pain. Causes of pain may be multifactorial and not always 
linked to disease activity. Nurses, through discussion and collaboration with the MDT and 
specialist pain teams, may help patients to manage this symptom. Some psychotherapeutic 
interventions can be helpful in managing the disease-related pain [EL 2]   
 Abdominal pain is common in IBD and is often the first symptomatic presentation of newly-
diagnosed or exacerbating disease [13, 172, 173]. It can influence HRQoL and anxiety due to 
its unpredictable nature and is often difficult to management [174, 175]. The cause of pain 
may be inflammatory such as stricturing disease, fistulae, fissures, or non-inflammatory  
which inlcude adhesions, fibrotic stricturing disease, co-existing functional GI symptoms. 
Extra-intestinal factors including gall stones, renal calculi, pancreatitis or joint and skin 
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complications may also cause pain [12]. Complaints of pain may trigger further 
investigations to uncover the cause [172, 175]. A sub-group of patients will continue to 
experience pain without evidence of active disease on investigation [175]. In this case the 
nurse needs to be empathetic and support the patient to manage their pain, which may be a 
manifestation of anxiety and depression or related to functional symptoms such as IBS [172, 
176-178]. 
Between 50 and 70% of patients experience pain during disease flares. Pain can also 
be associated with, or independent of, EIMs of which arthropathies are the most common 
with a reported prevalence of up to 46% [179]. Although treatment options for abdominal 
pain in IBD are sparse and thus far understudied [180], a treatment algorithm for IBD-related 
pain can support decision making in clinical practice [175].   
The nurse administrating analgesics must be knowledgeable about pharmacological 
pain control methods, associated side effects, and drug interactions of analgesics [172]. The 
psychological burden of pain can be recognised and addressed, and optimising IBD therapy 
may help. Opioids need to be used with caution as the use of these is complicated by 
dependance from chronic use and side-effects including serious infection and mortality [175, 
181], narcotic bowel syndrome characterised by abdominal pain of unexplained nature or 
intensity that worsens with increased doses of opioids, and gut dysmotility [182-184]. 
Tricyclic anti-depressants may be useful adjuvant analgesics [175, 185]. Once the cause of 
pain is established, patients could be educated about this and, in conjunction with the MDT 
and pain management teams, empowered to recognise and proactively manage their pain, for 
example by taking regular analgesia [186]. The Brief Pain Inventory is a valid and reliable 
tool for assessment of pain intensity and interference, and effectiveness of interventions, in 
both UC and CD [187]. Cognitive and behavioural psychotherapy may help patients to cope 
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with pain and improve their quality of life and functioning [175, 188, 189], but does not 
appear to influence disease course in IBD [190].  
 
2.14 Biological therapies 
 
N-ECCO Statement 2K 
The nurse involved in the management and delivery of biological therapy will ensure that 
appropriate screening and identification of any contraindications to therapy have been identified 
and recorded. Adhering to country-specific guidelines and local protocols enhances safe 
administration [EL 3]  
 
Biologic therapies are a key component of medical management of IBD. Ideally the choice of 
biological (originator or biosimilar) agent should be guided by patient condition and preference after 
thorough discussion of efficacy and safety characteristics with the healthcare professional [94, 191]. 
However numerous factors including physician experience, local funding arrangements, previous 
response to therapies, and disease behaviour and phenotype may override this choice [13, 191]. 
Careful patient selection and close follow-up may decrease the side-effect burden associated with 
these therapies [192], and it is vital that education regarding care and side effects is addressed prior 
to commencing medical therapy [193, 194]. The IBD nurse can facilitate such education and ensure 
information is conveyed in an uncomplicated manner [195]. The use of decision aids are useful when 
discussing adverse events as these present evidence-based data in a pictorial form, comparing risk to 
situations that patients can easily relate to, and enhancing their understanding [88, 196]. Thorough 
pre-treatment screening is vital to ensure that specific drug inclusion / exclusion criteria have been 
Downloaded from https://academic.oup.com/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjy020/4917790
by guest
on 05 March 2018
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjy020 
 
 
reviewed prior to administering biologics [192]. Screening includes blood monitoring, screening for 
active and latent infection to minimize the risk of reactivating dormant tuberculosis, radiologic and 
risk assessment including viral infection, immunization history and relevant co-morbidities e.g. 
cardiac history, previous cancer and dyemelinating syndrome [197]. In home administration, 
patients need to be counseled about the risks of opportunistic infections and made aware of their 
responsibilities to report infections and attend for monitoring. Screening results may require onward 
referral to other specialties such as respiratory or infectious diseases. It is advisable to view the 
ECCO online tool kits for therapies in IBD [198] and eguides. 
Any nurse responsible for biological therapies has to be skilled and competent in 
administering infusions, are aware of treatment side effects and know how to manage infusion 
reactions. Nursing practice should be underpinned with evidence-based protocols to protect the 
patient [191, 199, 200]. Checklists are a good safety measure for documenting that safe pre-
treatment steps have been addressed. The IBD nurse expertise can influence IBD care beyond direct 
patient contact, for example, to facilitate teaching general ward nurses to administer biological 
therapies or developing link nursing roles [201]. Patients also need educating about self-
administration [202]; assessment of the patient's competence and a training plan are essential and 
should be formally documented. 
Assessment of patients' clinical response to biological therapies, including therapeutic 
monitoring for possible drug side effects, potential complications, clinical and   biochemical 
response, can be undertaken by the IBD nurse following agreed protocols either at the time of 
administration, or at follow-up [203]. Some centres undertake this multidisciplinary review and 
management of patients on biologics via  virtual biologics clinics [204, 205].  
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N-ECCO Statement 2L  
Health maintenance is an integral part of routine preventative care for patients with IBD. Nurses can 
identify risk, screen, provide support and refer as necessary   [EL 4]   
 
Effective preventive measures to reduce morbidity, hospitalization, and surgery are critical 
to improving disease-free remission and quality of life [206]. Patients may not access routine 
preventative care mainly due to a clinical focus on IBD severity and symptom control, patient refusal 
to engage in prevention activities, and reimbursement issues may be influential [206].   
Health maintenance for patients with IBD includes preventing disease-related complications 
and disease- or treatment–related infections, and minimising adverse effects from medications 
[207]. The IBD nurse can take a thorough medical history soon after each patient’s initial diagnosis, 
including infectious disease, vaccination and smoking history. If the vaccination history is unclear, 
appropriate titers can be obtained in order to revaccinate prior to commencing immunosuppressant 
therapy [192]. Inactivated vaccines can be safely administered to all patients with IBD regardless of 
the degree of immunosuppressant [122]. Live virus and bacterial vaccinations, including BCG, are 
contraindicated in immunocompromised patients and annual inactivated influenza vaccination is 
recommended [208].  Further information regarding vaccinations can be found in section 4. 
  
Smoking is associated with increased risk of complications in CD, worsening of disease 
course at an earlier age, post-operative fistula formation, decreased response to medical therapy 
including biologics, and increased risk of most malignancies [209]. Smoking cessation could be 
addressed often [207] as patients with CD who stop smoking have fewer relapses when compared 
2.15 Health Maintenance 
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with continuing smokers [206]. Nurses should have the knowledge of local smoking cessation 
services to support patients. 
 
Patients with IBD have increased risk of developing metabolic bone disease, including 
osteopenia and osteoporosis, especially if previously treated with steroids; however, patients with 
CD are at risk for osteoporosis independent of steroid use [207, 210]. Diminished absorption of 
vitamin D and calcium increases the risk of osteoporosis. Ideally, regular measurement of 25-OH 
vitamin D levels and bone-density testing could be completed in all patients with additional risk 
factors for osteoporosis [210]. Primary prevention of fragility fractures includes adequate vitamin D 
supplementation, calcium intake, and physical activity [211]. The most effective medical therapies 
for osteoporosis include bisphosphonates [15].  
 
Colon cancer surveillance is recommended every one to five years for patients with IBD, 
commencing eight years after diagnosis, dependant on disease location. Annual colonoscopy is 
recommended in patients with the additional diagnosis of PSC [12].  
 
Women with IBD have a slightly increased risk of cervical dysplasia [122] and   young 
immunocompromised women should have a Papanicolaou (Pap) smear test twice in the first year of 
diagnosis and if the results are normal annual screening thereafter [157, 212]. Human papillomavirus 
vaccination is recommended for males and females ages 9–26 years [122, 192, 213]. 
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Development of non-melanoma skin cancer is associated with use of immunomodulators 
especially thiopurines, although patients with IBD have an increased risk of developing melanoma 
regardless of medication use [122]. Regular dermatological examination, including counseling, is 
recommended for all immunocompromised patients. Natural skin protection is suboptimal in 
patients with IBD [214], therefore ccounseling on prevention of sun exposure and wearing sun 
protective clothing, using sun block and avoiding tanning beds is recommended [122].  
 
2.16 Fatigue 
 
N-ECCO Statement 2M Nurses are well placed to identify, acknowledge and provide treatment and 
support for patients with IBD experiencing fatigue. Causes of fatigue may be multifactorial and 
nurses, through discussion and holistic assessment, may help patients manage [EL5]. Fatigue in 
IBD can be formally assessed using a validated generic or IBD-specific fatigue assessment scale, 
according to local availability [EL 2]. A holistic approach, incorporating assessment of psychological 
aspects, is recommended [EL3]  
 
Fatigue in IBD is a common complaint during relapse, and also affects over 40% of patients 
during remission [215]. It is widely described as ‘unpleasant, unusual, abnormal or excessive 
whole body tiredness which is disproportionate to or unrelated to activity or exertion and present 
for more than a month’ [216]. Not dispelled easily by rest or sleep, fatigue can have a profound 
negative impact on the person’s quality of life [217, 218]. The complex, invisible and changeable 
nature can make it difficult for patients to describe the experience of fatigue to others [51, 219]. 
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Fatigue is often poorly understood by healthcare professionals who may under-estimate the 
impact on the patient [220]. 
 
The aetiology of fatigue can be multifactorial and there may be a genetic predisposition 
[221]. Physical assessment, and biochemical and haematological testing may provide 
explanations. Persistently low iron stores, low haemoglobin, or raised inflammatory markers in 
the absence of bowel symptoms, are examples of reversible causes of fatigue. Low serum levels of 
vitamin D, IGF-1 and magnesium have also been linked to muscle fatigue, correlating well with 
self-reported fatigue, in patients with CD [222]. IBD Nurses can monitor this and provide advice on 
management. An early review suggested that one third of patients with IBD suffer from recurrent 
anaemia which may contribute significantly to fatigue. Active identification and treatment of 
anaemia was recommended [223]. Conversely, two studies have reported no correlation between 
anaemia and / or iron deficiency [224, 225]. However, fatigue appears to be most marked for 
female patients [224, 225] and those less than 60 years old [225], and thus has a greater impact on 
those perhaps with families, and of school and working age [226]. In addition, co-morbidity, a low 
level of education, and being unemployed may influence the perception of fatigue in IBD [227].  
A holistic assessment is necessary to identify physiological, psychological and any other 
potential cause of fatigue. Psychiatric conditions can co-exist with physical illness and evidence 
supports this relationship in IBD, with the prevalence of mood disorders such as anxiety and / or 
depression possibly up to three times greater than in the general population [176, 228]. Fatigue is 
associated with increased levels of disease-related worries and concerns in IBD, which in turn are 
associated with impaired HRQoL [226, 228]. Sleep quality, psychological factors such as anxiety, 
depression, disease-related worries, co-existing IBS and perceived disease-activity have 
consistently been identified as being strongly associated with fatigue in both patients with UC and 
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patients with CD [226, 229-235]. Fatigue is reported as being more severe in patients with CD [230, 
233], and in newly-diagnosed patients where it is independent of disease activity [229, 236]. 
Once identified, the IBD Nurse could monitor the patient to determine any improvement 
or worsening of fatigue symptoms. Optimisation of medical management is likely to alleviate 
fatigue in patients with UC over time [237], and once biochemical, haematological, or endocrine 
causes are excluded, the nurse can work with the patient to identify strategies and coping 
mechanisms which may help manage fatigue. Strategies could include: taking short naps during 
the day; reducing night shifts; exercising regularly; getting a good night’s sleep; eating a well-
balanced diet and keeping well-hydrated [238, 239]. In the absence of physiological causes of 
fatigue, moderate activity and psychological interventions, particularly solution-focused therapy 
and exercise, appear to be the most promising [237, 238], but more research is needed [240, 241]. 
Patients may need encouragement to report fatigue to, and seek help from, health professionals 
[242], but some may be reluctant to discuss fatigue if they perceive that no cure is available it 
[243].   
 
 
 
3. Advanced IBD Nursing  
3.1 Definition, requirements and skills 
In this document the term ‘Advanced IBD Nurse’ refers to experienced adult or paediatric nurses 
caring for people with IBD at an advanced level attained by extensive clinical practice, professional 
development, formal education and research skills  [244, 245]. 
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N-ECCO Statement 3A 
 The Advanced IBD Nurse is an autonomous clinical expert in IBD who is responsible for the 
assessment and provision of evidence based care planning and treatment evaluation, and who 
provides practical information, education and emotional support for patients with IBD. They 
will practice within their own professional competency and accountability, supported by 
protocols or guidelines in collaboration with the MDT [EL 5] 
 
The Advanced IBD Nurse is often referred to as a clinical nurse specialist, advanced practitioner or 
consultant who works autonomously in collaboration with the MDT and patient. The Advanced IBD 
Nurse plays an important role in assessment, diagnosis, treatment planning, evaluation, monitoring, 
surveillance, education, health promotion and practical and emotional support for a caseload of 
patients with IBD, within the scope of their own professional practice and limitations [246]. The 
Advanced Nurse will work within local, national, or international guidance or protocols. Although the 
specifics of these roles will vary depending on national and local needs, the international literature 
suggests commonalities in the expected skills required for advanced practice. These include 
competencies in advanced clinical skills, which may include physical assessment, performing and 
interpreting endoscopy or prescribing; the development of practice standards and provision of 
evidence-based care; ability to analyse, critique and evaluate evidence and outcomes; critical thinking; 
publishing practice innovations or audits; the development of original nursing research; leadership; 
education; and change management [245, 247-250].  
Downloaded from https://academic.oup.com/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjy020/4917790
by guest
on 05 March 2018
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjy020 
 
 
The Advanced IBD Nurse works as part of the IBD-MDT, enhancing patient care and experience, 
providing efficient holistic and accessible care [EL 5]. The advanced IBD nursing role additionally 
includes education, research, service development and leadership. In order to achieve these skills a 
broad clinical experience and development of clinical competencies is ideally supplemented by post 
graduate education [EL 5]  
Although the largest proportion of the Advanced Nurses’ time is spent in direct clinical practice, 
education, research, leadership and service development activities are essential role components [245, 
246, 248, 250, 251]. There is no consensus on the expected level of education which varies between 
countries and organisations and may be governed by national professional standards and regulatory 
requirements [244]. It is generally agreed that Advanced Nurses should have a first degree at 
minimum though many will be educated to Masters or Doctorate level. Although research remains a 
recommended core activity of the Advanced Nurse role, little time is dedicated to it compared to 
clinical care [245, 251-254]. Advanced IBD Nurses are well placed to undertake research and explore 
areas which impact the patient’s quality of life, psychological health, the effect on family, 
employment and education, and financial implications of disease, all of which are areas of concern for 
patients. Lack of dedicated time is often cited as one barrier to integrating research into the role. 
Therefore it is essential to ensure this component is acknowledged in role descriptions and job plans 
and nurses are supported to attain the skills or confidence they often feel they lack to conduct research 
[255].  
Leadership is pivotal to effecting change in clinical practice and enhanced leadership skills can 
improve team effectiveness and lead to provision of more patient-centred care [256]. Components of 
effective leadership include practice leadership; role modelling; promoting patient safety; caseload 
management; evaluation of services or interventions; facilitating improvements or innovation; 
consultancy; being able to develop self and others; and change management [245, 257]. Leadership 
may be demonstrated through problem solving, critical thinking, listening and engagement with the 
N-ECCO Statement 3B  
3.2 The Advanced IBD nursing role  
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MDT team or stakeholders [245]. Networking and sharing of practice via national and international 
groups is an important aspect of leadership. N-ECCO is one international nursing network which 
enables practice development and best practice across several countries to be shared.  
Locally, each hospital is likely to have its own expectations and objectives for individual specialist 
nursing roles. The development of explicit clinical competencies is often advocated as a means to 
achieve the necessary advanced skills [247, 250, 253, 258]. The development of policies, protocols or 
guidelines are useful frameworks to support the clinical activities of the Advanced IBD Nurse. 
However, Advanced IBD Nurses also work beyond protocol-led care, with freedom to use their 
clinical acumen whilst acknowledging professional limitations, and seeking advice where appropriate. 
 
 
 
3.3 The Advanced nurse role in the planned review, care and follow up of stable 
patients. 
N-ECCO Statement 3C 
 The Advanced IBD Nurse can conduct regular patient reviews face to face, via telephone or 
electronically in order to monitor treatments, and arrange appropriate investigation as required, 
with local policy or guidance [EL5]. Limitations of remote contact must be considered and skilled 
judgement used in knowing when further assessment is required [EL5].  
 
Patients with IBD require long-term outpatient follow-up and surveillance. Disease activity often 
fluctuates over time requiring maintenance therapy and acute interventions for disease flares. 
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Complex disease management requires a specialised MDT approach which enhances the level of 
continuous care and improves outcomes. In this dedicated team, a key role for the Advanced IBD 
Nurse is increasingly being recognised [259]. Advanced IBD Nurses are consistent team members 
who work with patients over a period of time. This continuity is one of the advantages, over other 
groups of healthcare professionals, for Advanced IBD Nurses involvement in follow-up [260, 261].  
 
Advanced IBD Nurses facilitate the follow-up of patients during relapse and in remission, providing a 
link between the family doctor, hospital care, and rapid access in the event of a flare up [262, 263]. 
The Advanced IBD Nurse who reviews patients independently of medical colleagues has an added 
responsibility to raise any issues of concern that fall beyond their scope of practice with appropriate 
medical colleagues, and be aware when onward referral is necessary. Patients receiving conservative 
management in specialist nurse services report high levels of satisfaction, improved ability to live 
with symptoms and a better quality of life [264]. Nurse-led clinics have been shown to almost halve 
the number of physician visits, thus reducing medical workload in IBD units [265]. 
 
3.4 The Advanced IBD Nurse caring for complex patients 
N-ECCO Statement 3D  
The Advanced IBD Nurse plays a key role in the IBD-MDT when caring for complex patients, and will 
be able to assess the patients' care needs and can refer patients on, if needed [EL5].   
 
Advanced IBD Nurses have a pivotal role within the IBD-MDT as they can provide direct care as well 
as holistic support [266, 267] and make a significant contribution to patient experience, including 
facilitating complex decision-making regarding patient care. The Advanced IBD Nurse develops the 
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role to provide social, physical and psychological support in addition to providing education and 
promoting understanding for the patient and families when IBD becomes complex. Further, the 
Advanced IBD Nurse plays a key liaison role, acting as the patient’s advocate at IBD-MDT meetings 
and ensuring there is focus on managing IBD in the context of the patient's life, rather than just in 
terms of disease activity [88]. 
The changing demands of IBD in terms of complex treatment algorithms, place the Advanced IBD 
Nurse at the centre of care to ensure that patient needs are met through ongoing delivery of high 
quality evidence-based care.  
 
3.5 The Advanced IBD Nursing Assessment  
N-ECCO Statement 3E  
The Advanced IBD Nursing assessment is both wide ranging and able to focus on specific areas of 
concern. The nurse may use biomarkers, imaging and physical assessment including endoscopy 
providing appropriate training has been undertaken. The Advanced IBD Nurse will be aware of 
existing assessment tools that may be useful aids in the management of patients with IBD and their 
related health problems [EL 5] 
 
To develop a care plan for any patient in any situation whether face to face in clinic, or via telephone 
or email, a thorough, competent and relevant assessment is vital [246, 251, 268, 269].  At the first 
meeting, a comprehensive ‘IBD history’ may be recorded, including age at diagnosis, extent and 
duration of disease, any surgical procedures, current and past medication, any drug side effects or 
intolerances, dietary triggers or intolerances. It is also important to gauge the patient’s understanding 
of IBD, its management and the care they are receiving. Assessment proformas are a useful tool to 
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ensure a consistent approach, and can be used by nurses at differing levels [269]. Assessment of 
current disease activity including EIMs, dietary history, HRQoL, coping strategies, psychological 
well-being, social support and health behaviours e.g. smoking, drug adherence could be reviewed. 
Confirmation of medication used, including complementary and alternative medicines (CAMs) or 
over the counter preparations, as well as response or adverse effects of prescribed treatment. Fever, 
nausea, vomiting, weight loss, fatigue or other signs indicative of active disease can be identified. 
Validated disease activity scoring systems, such as The Harvey Bradshaw Index (HBI) for CD, or 
Simple Clinical Colitis Activity Index (SCCAI) for UC [153, 270, 271] aid consistent assessment of 
disease severity, enable objective measurement of improvement or deterioration in the patient’s 
condition, allow for revision of treatment plan and support audit and research.  
 The Advanced IBD Nurse may use other assessment methods such as abdominal examination, 
interpretation of endoscopy, blood tests, faecal calprotectin, radiology, histology and other imaging 
tests, all according to training, skills and local protocol [272]. Objective measures such as the 
Inflammatory Bowel Disease Questionnaire (IBDQ) or the Hospital Anxiety and Depression Scale 
(HADS) are useful to assess HRQoL and psychological well-being [273, 274]. Other scoring tools 
may be appropriate in certain situations, such as pain or fatigue scores.  
Despite reporting similar levels of stress that are unrelated to work, patients with IBD have a lower 
employment rate, higher disability rate and more days of sick leave compared to the general 
population, but have enhanced social support [275-277]. The Advanced IBD Nurse can assess the 
social impact and the patients’ existing resources both within the family and wider social structure. It 
is useful for the Advanced IBD Nurse to have some knowledge regarding national employment laws 
for people with a chronic disease, and to refer the patient for additional support, such as country 
specific patient support groups and charities, if needed. Completing a thorough holistic assessment 
enables the Advanced IBD Nurse to implement appropriate plans of care and identify other direct and 
indirect effects such as psychological morbidity, presence of functional GI disorders, problems with 
sexuality, fertility, drug monitoring and compliance, incontinence, fatigue and anaemia [278].  
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3.6 The Advanced IBD Nurse role in managing Advice Lines  
N-ECCO Statement 3F 
 Advice Lines are considered a key element of an advanced IBD nursing role and may improve 
clinical and service outcomes [EL 5]. This type of contact provides rapid access to a specialist nurse. 
It is suitable for providing many aspects of care, information and support, and the assessment, 
investigation and treatment of the unwell patient [EL 3]. 
 
From the patient perspective, the rapid and direct access to an IBD nurse is of great 
importance. [261, 279]. An IBD service including advice lines (ALs) has been identified as 
an element of “best practice” in an observational study in eight European countries [280]. 
 
Besides the direct effects of IBD, patients may experience other life challenges as a 
consequence of their condition. Issues around schooling, employment, smoking, diet, pain, 
fertility and pregnancy, travel, sexual and other relationships, adherence, stigma, transition 
from childhood to adulthood, fatigue and more may be addressed via a telephone or e-mail 
AL [281-284]. 
 
ALs managed by IBD nurses is safe and cost-effective. ALs can reduce out-patient visits and 
'avoid' inpatient stays [285-288]. Furthermore, ALs can reduce the need for some face to face 
reviews but may also, wrongly, be perceived as a means of keeping patients away from 
outpatient clinics [289]. ALs provides prompt and appropriate expert nursing advice, and 
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urgent access to clinics and to consultant support. Advanced communication skills must be 
utilised when using remote assessment especially as nonverbal cues cannot be used. 
Appropriate levels of practitioner competency and knowledge are emphasised [290]. 
Protocols may enable the development of agreed expectations of an AL service [280]. Local 
protocols will reflect local practicalities and legalities and outline the aim, responsibility, and 
the remit agreed for those involved in running an AL [287, 291]. 
 
3.7 Patient information and education 
N-ECCO Statement 3G 
 The Advanced IBD Nurse assesses understanding and, informed by current evidence, 
provides education to patients with IBD and their significant others based on individual 
needs, preferences and coping ability aiming to empower the patient to live well with IBD. 
The Advanced IBD Nurse can direct the patient toward trusted sources of educational 
materials [EL 5] 
 
The Advanced IBD Nurse can be perceptive to the patient’s educational needs and provide 
essential information and education for patients, which may take various forms e.g. group, 
individual, or family-focused [292]. Patient education may need to be repeated and supported 
by other sources e.g. phone, written information, electronic means, and country-specific 
patient support groups.  
 
A wide range of information and videos of IBD of variable quality are available on the 
internet, and may only be used as supplemental information to more individualised education 
[293-295]. The Advanced IBD Nurse need to be able to identify, analyse and classify relevant 
literature and information to guide the patient.  
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Studies of structured patient education programmes have, to some extent, shown an increase 
in the participants' level of knowledge and empowerment [296], but no significant effect on 
HRQoL [297-300]. Since some patients choose not to participate in structured patient 
education and a broad range of tailored alternatives has to be available [301].  
 
There is no clear evidence that self-management programmes for patients with UC either 
improve health or increase wellbeing [302] but despite this, IBD nurses are encouraged to 
facilitate self-management [303]. There may be reduced economic cost for patients allocated 
to self-management compared to usual treatment [304]. Education towards self-management 
complements traditional patient education in supporting patients to live the best possible 
quality of life with their condition. As well as teaching problem-solving skills, a central 
concept in self-management is self-efficacy—confidence to carry out behaviour necessary to 
reach a desired goal [305].  
 
IBD teams are encouraged to support country specific patient support groups and charities' 
educational and open forum sessions, allowing patients to become more involved in shaping 
local services [199]. This also improves patients’ knowledge of IBD which is associated with 
improved coping and adherence to treatment [299, 306]. Recently diagnosed patients 
primarily glean information from the doctor and the internet, but two thirds of the patients 
prefer information from a nurse specialist [307]. For patients with special needs e.g. medical, 
cultural, mental, or social; the Advanced IBD Nurse plays a key role in linking to appropriate 
services in the MDT.  
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Advanced IBD Nurse, along with the IBD-MDT, plays a key role in the development, 
introduction, delivery, monitoring and evaluation of electronic health technologies [EL 5] 
 
Few studies have explored different e-health interventions in IBD. Most had an observational 
design but a small number were RCTs, including one which revealed significant beneficial 
effects of a telemedicine system on visits to and contact with health care services [308].   
Three systematic reviews revealed that e-health interventions are safe, and effective for the 
subgroup of patients studied [309-311]. In general, study interventions and outcomes were 
heterogeneous, and interventions ranged from ALs and virtual clinics to smart-phone 
applications. The study participants were mainly patients with quiescent disease. Although it 
is not always clearly described, IBD nurses appear to play a key role in reviewing patient-
reported data and taking action as necessary [312-314]. Patients with IBD have a positive 
attitude towards e-health and self-management approaches as long as they are well, but rapid 
and easy access to both gastroenterologists and IBD nurses remain an important supplement 
[261, 312]. Advanced IBD Nurses naturally become involved in the implementation and 
operation of most e-health initiatives, and may be involved in e-health projects. Their routine 
and frequent use of PROMs, well-developed communication skills and competences are 
essential when establishing and maintaining any remote IBD service. 
 
 
 
N-ECCO Statement 3H  
3.8 E-health Nursing  
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The adolescent and young person with IBD needs a structured transition programme when 
transferring from paediatric to adult care (EL2). The model of transition may vary according to 
local arrangements (EL5). The Advanced IBD Nurse is pivotal in the transition process by liaising 
with the adult and paediatric MDT to ensure a flexible and individualised transition process with 
the patient at the centre (EL3) 
Transition is described as the purposeful and planned movement of care from a paediatric to adult-
orientated health care service for young adults with chronic medical conditions, and  handover of 
health responsibility from parent to adolescent [315]. Transition differs from transfer in that 
transition is structured, planned and considered [316]. Effective transition programmes empower 
young adults to take responsibility for, and manage their own health, by equipping them with the 
required knowledge and skills underpinned by appropriate health care support. Transition 
programmes yield significant improvements in disease outcomes and HRQoL [317, 318]. 
 
Differing models of transition have been described, which vary dependent upon geographical area, 
access to public health care and differing health care models. However, the importance of effective 
transition for any adolescent with chronic illness, and of the role of a care coordinator in improving 
patient outcomes within this vulnerable group, has been described in international literature [319] 
and supported by international IBD guidelines [320-322]. The Advanced IBD Nurse is well placed to 
undertake the key role of co-coordinator [320] with responsibility for transition [317, 323]. 
International audits have identified that alongside other clinical benefits, services with an IBD nurse 
within the MDT are associated with successful transition of adolescents from paediatric to adult-
orientated IBD services [323, 324].  
 
 
N-ECCO Statement 4A 
4.1 The advanced IBD nurse role in transitional care 
4. Advanced IBD nursing care for particular situations 
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4.2 IBD and Travel 
 
N-ECCO Statement 4B  
Whenever necessary, the patient with IBD planning to travel receives appropriate pre-travel 
consultation and education regarding the risks and practical issues of travel with IBD. The Advanced 
IBD Nurse can be a source of information, support nd referral to relevant resources. Special 
consideration should be given to patients on immunosuppressants [EL4]  
 
 
4.2.1 Pre-travel consultation:  
Foreign travel is associated with an increased risk of travel-related morbidity caused through 
exacerbations of IBD, acquisition of infectious diseases endemic to the destination, and availability 
of healthcare and medicines whilst abroad [325, 326]. Patients receiving immunosuppressive 
medication, such as azathioprine, methotrexate and 6-Mercaptopurine, have increased susceptibility 
to these infections in addition to an attenuated immune response to vaccinations [325, 327-330]. 
Detailed pre-travel consultations and vaccinations are advised to ensure travellers have the 
appropriate education and resources to stay healthy during their journey [325, 330-332]. 
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Pre-travel preparation and education among patients is poor with many failing to obtain any formal 
pre-travel advice, having inadequate travel insurance to cover IBD, and lacking awareness regarding 
vaccinations [326, 333-335]. Healthcare professionals’ knowledge and provision of pre-travel 
counseling and adherence to international guidelines is also poor [336, 337], particularly regarding 
avoidance of live vaccines for those on immunosuppressive medication [338-340]. 
 
The pre-travel consultation may be an MDT approach involving the Advanced IBD Nurse, 
gastroenterologist, family doctor, travel clinic and, for complex patients, the infectious diseases 
team. Consultation includes support and encouragement for travel – IBD need not restrict patients 
from foreign travel – and sign-posting to IBD-specific travel experts and resources [340]. The 
Advanced IBD nurse could be involved in the discussion regarding travel destination and related level 
of risk, particularly for those on immunomodulator therapy, including the importance of obtaining 
travel insurance to cover IBD and  food and water precautions to avoid travelers’ diarrhoea.  
 
4.2.2 Vaccination advice  
Administration of live vaccines to patients on immunosuppressant medication, such as azathioprine, 
6-Mercaptopurine and methotrexate, is contraindicated. Serious and potentially fatal infections can 
arise due to extensive replication of the vaccine strain, which does not happen with inactivated 
vaccines. Some vaccinations for travel such as yellow fever, typhoid and BCG are only available in a 
‘live form’. It is recommended to use a standardised checklist for immunisation for opportunistic 
infections [325].  Good communication between the IBD-MDT, travel clinics and patient is therefore 
essential to ensure safe vaccination and travel. The ECCO ‘evidenced – based consensus on the 
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prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease’ 
details individual vaccination required prior to commencing and discontinuation of 
immunosuppressant therapy, for example, varicella vaccine must be administered 3 weeks prior to 
starting treatment and subsequent immunisation can only be administered after 3-6 months after 
discontinuation [192] .  
 
 
4.3 Pregnancy and fertility   
N-ECCO Statement 4C  
The Advanced IBD Nurse plays a pivotal role in supporting the patient who is considering pregnancy. 
Pre-conception counseling addressing fertility and pregnancy outcomes would ideally start as early 
as possible with both males and females to support decision making (EL5). Controlling active disease 
prior to and during pregnancy is important (EL3, EL5)  
Reproduction and pregnancy in patients with IBD are described in the ECCO guidelines [157]. 
 
4.3.1 Fertility 
Compared with an age-matched population, female patients with quiescent IBD do not have 
decreased fertility. Low birth rates among woman with IBD are often due to personal choice rather 
than disease related infertility [341-344]. The knowledge of women with IBD regarding pregnancy is 
often poor [345, 346], requiring assessment by the Advanced IBD Nurse and provision of appropriate 
disease-related education.  
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Women with active disease may experience sub fertility and problems achieving pregnancy [347]. 
IBD-related complications such as abscesses and fistulae in the genital region may result in sexual 
abstinence. Restorative proctocolectomy with ileoanal anastomosis has been associated with 
reduced sexual activity due to scarring and formation of adnexal adhesions [343, 348, 349]. 
 
There is no reported evidence of medications affecting female fertility [157]. Male fertility may be 
decreased by methotrexate which is teratogenic, and sulfasalazine which can cause oligospermia, 
reduced sperm motility and abnormal sperm morphology [350-353], although these effects are fully 
reversible within a few weeks of stopping the drug. Sub fertility in male patients may also be related 
to poor nutrition, depression and reduced libido [347]. Proctocolectomy in men may lead to 
impotence or ejaculatory difficulties [354].  
 
4.3.2 Preconception care 
Preconception counseling is recommended as women with IBD who conceive while in remission are 
more likely to remain in remission during the course of their pregnancy, although  woman with UC 
have more disease activity during pregnancy than those with CD [354]. 
 
Family planning and breast feeding issues could be discussed with both males and females before 
treatment, as some patients may wish to stop treatment before conception [355]. The Advanced IBD 
Nurse may address specific patient concerns to optimise control of disease, avoid inappropriate 
medication cessation and discontinue medications that may adversely affect pregnancy. Patients 
often have concerns about IBD inheritability, the risk of congenital abnormality and medication 
teratogenicity [342, 356]. To provide optimal evaluation and treatment, the Advanced IBD Nurse as 
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well as the IBD-MDT needs to be aware of the diverse spectrum of conditions and problems that 
may be encountered.  
 
4.3.3 Pregnancy and post-partum care 
 
N-ECCO Statement 4D 
An MDT approach is recommended as appropriate (EL3, EL5). The Advanced IBD Nurse can be a 
source of support and education during the pregnancy and post-partum period, in particular, 
regarding breast feeding and medication safety (EL5) 
The severity and extent of disease at conception appears to influence the course of disease during 
pregnancy; approximately two-thirds of woman in remission will stay in remission, whilst active 
disease at conception is likely to persist and possibly deteriorate in two-thirds of women during 
pregnancy [157].   
  
Disease activity is the main adverse factor predisposing to intrauterine death, prematurity and low 
birth weight babies [357, 358]. The balance between maintaining or discontinuing IBD treatment, 
which increases the risk of an acute exacerbation requiring prompt treatment [157], needs to be 
weighed up for each individual. Women with IBD often overestimate the harmful effects of 
medication while underestimating the harmful effects of an IBD flare during pregnancy [356, 358, 
359]. Continued drug therapy may be necessary and the patient counseled  of  risks of discontinuing 
medication  [360]. 
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If pregnant women require hospitalisation for IBD, they may be transferred to a tertiary center with 
a MDT [356, 359, 361-364]. Labour and delivery plans should be discussed between the 
gastroenterologist, obstetrician and patient. The choice of vaginal or caesarean delivery may be 
influenced by IBD and / or disease activity and patient choice [157]. Breastfeeding is strongly 
encouraged due to the reported benefits for both mother and child. Breastfeeding does not increase 
the risk of disease flare and may even provide protection against flare in the postpartum year [365, 
366]. The Advanced IBD Nurse can play a pivotal role throughout the woman’s pregnancy, providing 
advice of the safety of medicines whilst breastfeeding and offering timely reviews to minimise the 
risk of relapse [367].  
 
 
 
4.4 The IBD Nurse role in IBD iron deficiency and anaemia 
 
N-ECCO Statement 4E 
The Advanced IBD Nurse is well placed to identify iron deficiency anaemia, and facilitate iron 
supplementation in patients with IBD, monitoring both effect and side-effects of treatment [EL5]  
 
Anaemia is a common EIM in IBD, and prevalence depends on disease activity. Approximately 25% of 
patients will have anaemia, although prevalence has been reported at 50% amongst IBD outpatients 
observed over a two year period [368].  Prevalence is slightly higher in patients with CD when 
compared to UC [369]. Anaemia is considered present if haemoglobin levels are < 12 g/dl in non-
pregnant women and < 13 g/dl in men [370]. The detection, treatment and monitoring of anaemia 
and iron deficiency are described in the ECCO guidelines [371].  
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The main causes of anaemia in IBD are inflammation and/or iron deficiency. Anaemia of chronic 
disease (ACD) is caused by inhibited bone marrow activity and reduced iron uptake due to 
inflammation [371]. Iron deficiency anaemia (IDA) in patients with IBD may be caused by a 
combination of blood loss from the bowel, malnutrition with reduced iron intake, or impaired iron 
uptake  [368]. The Advanced IBD Nurse investigates and interprets results to identify IDA and ACD 
and its consequences, and provides treatment as appropriate. This includes oral iron, IV iron 
therapy, with monitoring for effects, side effects and adherence to treatment, and referral to 
dieticians or gastroenterologists as required.  
 
4.5 Caring for the patient undergoing stoma and ileal-anal pouch formation  
 
N-ECCO Statement  4F 
 The Advanced IBD Nurse is well placed to support the patient in the perioperative period by being a 
source of education and referring to appropriate members of the MDT, particularly the stoma nurse. 
Psychologists, sexual therapists and country specific patient organisations can help with information 
provision and psychological support (EL5)  
 
Many patients are understandably distressed at the thought of undergoing either planned or emergency 
surgery, and the Advanced IBD Nurse plays a key role in coordinating healthcare professionals. 
Patients may undergo a colonic resection without stoma formation or require further surgery to 
include restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). The main indication 
for IPAA is in patients with medically refractory UC [372, 373], or dysplasia or cancer developed 
from underlying UC.  
Downloaded from https://academic.oup.com/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjy020/4917790
by guest
on 05 March 2018
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjy020 
 
 
 
For any complex surgical procedure, the patient is best managed within an MDT including the stoma 
care nurse. In the event of stoma formation, the stoma care nurse provides essential support and 
education to the patient and their family prior to surgery, during the hospital stay and following 
discharge [374].  
 
Stoma and IPAA surgery provide numerous benefits including long term symptom relief [372, 375] 
although recent evidence suggests that while outcomes are often better than anticipated, some patients 
require a long time to decide about stoma surgery and find benefit from pre-operative contact with 
another patient with IBD living well with a stoma [29] .  
 
4.5.1 Caring for the patient with an ileoanal pouch 
 
N-ECCO Statement 4G  
 The Advanced IBD Nurse is well placed to identify problems associated with pouch function 
including pouchitis and dysfunction, and quality of life, fertility and pregnancy, incontinence and 
sexual issues. The Advanced IBD Nurse can support the patient and provide education and 
information regarding the pouch, referring on as appropriate (EL 5)  
 
Pouch dysfunction can occur following surgery and can be caused by pouchitis, cuffitis, irritable 
pouch syndrome, CD, or pouch fistula. Pouch failure requiring surgery and removal of pouch can 
sometimes occur [372] and diagnosis depends on endoscopic and histological findings in conjunction 
with symptoms [376]. 
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Approximately 25% of patients will develop recurrent pouchitis, with 5% enduring chronic pouchitis 
requiring maintenance therapy or, on rare occasion, pouch excision [372]. Factors associated with an 
increased risk of pouchitis include PSC, EIMs, and nonsmokers. Controversy surrounds other risk 
factors such as extent of colitis and backwash ileitis. The etiology of pouchitis is unknown, but 
theories range from genetic susceptibility, bacterial overgrowth, ischemia, and faecal stasis, to a 
recurrence of UC in the pouch, a missed diagnosis of CD, or possibly a novel third form of IBD [372]. 
Some patients with symptoms of pouchitis will not have inflammation, but rather, irritable pouch 
syndrome [372]. Symptoms related to pouchitis include increased stool frequency and liquidity, 
abdominal cramping, urgency, tenesmus, and pelvic discomfort. Fever, EIMs and rectal bleeding may 
also occur, although the latter is more often related to inflammation of the rectal cuff than to 
pouchitis [373, 377]. Faecal incontinence may occur after IPAA without pouchitis, but is more 
common in patients with pouchitis [372]. The Advanced IBD Nurse, other members of the MDT and 
the stoma / pouch care nurses provide support for the patient if complications develop, and if the 
pouch needs to be removed. 
 
4.6 IBD in elderly  
 
N-ECCO Statement 4H   
The Advanced IBD Nurse is in a position to assess the health risks or frailty of elderly patients with 
IBD regarding medication (polypharmacy), medical history, co-morbidities, bone density, 
incontinence, cognitive deficit and depression (EL5)  
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Care of the elderly patient with IBD is extensively covered in the ECCO topical review [378]. A key 
characteristic of the health status of the elderly is its large heterogeneity in terms of the effects of 
ageing on individuals’ quality of life, functional limitation and the type of diseases and conditions 
affecting them. 
Until recently, little data existed about IBD in the older person. Possible explanations for this include 
higher rates of exclusion from clinical trials, primarily due to concerns about aging itself increasing 
the risk of adverse events, and less endoscopic procedures performed within this population [379]. 
Approximately 25-35% of people living with IBD are elderly, with 15% of those being diagnosed ‘de 
novo’ with conditions in later life. Incidence rates of UC are currently greater than for CD in the older 
person, but increased rates are anticipated in both disease groups [379, 380]. Effects of ageing include 
frailty, degeneration, reduced recovery capacity, co-morbidity,  polypharmacy and shortened life 
expectancy [379]. The older person with IBD can be stratified into one of two subgroups: elderly 
onset and elderly IBD patient. 'Elderly Onset IBD' is defined as the first presentation / diagnosis of 
IBD in an individual aged 60 years and over, whilst an 'Elderly IBD Patient' is an individual aged 60 
years or over with an established IBD diagnosis. Aging with a known diagnosis of IBD may increase 
the risk of complications, prolonged hospitalisation, and higher incidences of morbidity and mortality 
[379-381].  
When making management decisions for care of the elderly with IBD, the Advanced IBD Nurse needs 
to assess the patient’s frailty and acknowledge the difference between the chronological and 
biological age [382]. Validated measures of frailty may be used [383].   
 
4.6.1 Health risks in the elderly with IBD 
The principles of medical management for elderly individuals with IBD are the same as for any adult 
patient: to induce and maintain remission of symptoms, promote quality of life and prevent 
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complications of disease. However, advancing age can bring specific challenges including depression 
[384-386]. The Advanced IBD Nurse requires an understanding of elderly patients’ needs including 
social history and support network, to identify when intervention and referral to outside agencies 
such as social care is required.   
 
Between 26 - 48% of patients with IBD have decreased bone density and a 40% higher risk of 
fracture, when compared to a non-IBD population. Older age is also a risk factor for development of 
osteoporosis. However, establishing the degree of bone loss due to aging is difficult in patients with 
IBD due to confounding factors of corticosteroids use, poor nutrition, duration of disease and 
ongoing active inflammation, and body habitus [384, 387-389].  
 
An elderly patient with at least two chronic diseases will usually exceed the arbitrary threshold of 
more than five medications. The consequences of polypharmacy include greater health-care cost, 
increased risk of adverse drugs events, drug interactions, medication non-adherence, reduced 
functional capacity and multiple age-related syndromes. Polypharmacy may be more common in 
elderly patients with IBD and the potential for drug interactions must be considered. Problems with 
administration, for example, rectal therapies, merit careful consideration by the Advanced IBD Nurse 
[390-392].  
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The Advanced IBD Nurse provides a pivotal and important role in the care of patients with IBD, 
within the IBD-MDT and to health care providers. Nurse-led services including telephone advice lines 
and out-patient clinics have been demonstrated to be cost-effective and beneficial to patients and 
healthcare providers [EL3]
  
 
 
Although generally accepted as beneficial to patients and services, a key challenge for the Advanced 
IBD Nursing role since its inception has been to demonstrate this benefit. This  specialist role was the 
first to be reviewed for the Cochrane database [393] however, reviewed studies were assessed as 
having low methodical quality resulting in benefits being difficult to quantify. ECCO, N-ECCO, and the 
N-ECCO Research Forum continue to work to improve the quality and transferability of research into 
the Advanced IBD Nurse role.    
 
 
5.1 Organisational benefits 
A number of organisational benefits of the Advanced IBD Nurse role have been demonstrated, 
including greater integration of care across multidisciplinary teams [394], and the bridging of 
primary and secondary care interfaces. As discussed in Section 3, Advanced IBD Nurses play a vital 
role within the IBD-MDT [88, 395-398]. Patients report greater satisfaction of care with an IBD nurse 
in the team [399], with  improved access to better co-ordinated care, and better education and 
support for them and their families/carers [395]. In the UK, centres with an Advanced IBD Nurse in 
N-ECCO Statement 5A  
5. Benefits of an IBD nurse   
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the MDT have fewer hospital admissions, provide access to self-management approaches for disease 
control, and give greater choice regarding delivery of follow-up care for patients [261]. One Austrain 
IBD service consisting of a gastroenterologist, an IBD nurse, a weekly designated IBD clinic, a joint 
medical–surgical clinic for IBD and a regular time for radiology review was developed and co-
ordinated by the Advanced IBD Nurse. Healthcare utilisation, number of admissions and disease 
burden decreased significantly demonstrating financial and clinical gains for patients [400]. Benefits 
have also been demonstrated in transition services where the skill of the Advanced IBD Nurse can 
facilitate adjustment to the many demands faced by the young person with IBD and their family as 
they progress to adult IBD services [397, 401-404]. 
 
As discussed in Section 2, IBD nurses at any grade may be involved in delivering biologic therapies, 
but the service delivery of this treatment modality is now routinely managed in many centres by the 
Advanced IBD Nurse [191, 397, 398]. One UK audit found that 90% of IBD nurses had direct clinical 
responsibility for delivering biological services within their institution [405], a role which 
incorporates patient counseling, safety pre-treatment screening, and delivery of therapy. The 
Advanced IBD Nurse is influential in improving quality of life outcomes in patients through increased 
safety monitoring [406, 407]. Monitoring for side effects and adverse blood results is described as 
vital ‘rescue work’ [408], and is essential for patients on immunosuppressive therapy to minimise 
potentially serious adverse events such as neutropenia or myelotoxicity, and reduce the burden of 
disease severity and activity. Recent advances with therapeutic drug monitoring, including 
measurement of trough levels of drug and antibody detection, further underpins the need for 
Advanced IBD Nurses. ‘Virtual’ review of patients receiving biological therapies provide a more 
cohesive monitoring model with ease of two-way feedback for patient and clinician, helping to 
ensure the most benefit for patient and cost effectiveness is obtained from therapy [205, 398]. The 
Advanced IBD Nurse will often oversee this review, ensuring relevant clinical information and patient 
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outcomes are reported appropriately. Despite this, many IBD centres across Europe delivering 
biological services still do not have access to an Advanced IBD Nurse as part of the MDT. By 2013, a 
quarter of UK hospitals still had no IBD nurse [409] and a 2016 Italian audit revealed that less than 
40% of centres treating patients with biological therapy had access to a specialist IBD nurse [266], 
highlighting the need for continued work and investment in this area. 
 
5.2 Better access to care, reduced waiting times, and cost benefits arising from an IBD Nursing 
service 
 
Patients describe the IBD nurse as a constant and reliable source of contact providing immediate 
advice [285, 393, 395, 410]. Prompt access is the most frequently cited benefit of an IBD nursing 
service from the patient perspective. Increased access to the IBD team via telephone AL managed by 
Advanced IBD Nurses, has also been demonstrated to significantly reduce costs associated with 
unscheduled primary and secondary healthcare visits [259, 285, 410]. High levels of patient contact 
episodes are recorded via helpline services across Europe [285, 411].  Where a monetary tariff can 
be attached, ALs generates income for the IBD service [285, 288, 412]. Studies demonstrate that 
outpatient visits and hospital admissions can be avoided through counseling by phone or e-mail with 
the IBD nurse [73, 259, 288]. AL services enable Advanced IBD nurses to conduct ‘rescue work’ [408] 
and facilitate faster access to procedures and other relevant departments [259, 288].  
 
Patients with quiescent disease can often be managed by IBD nurse led telephone clinics, with 
proven cost-effectiveness and acceptability to patients and health care providers [413-416]. The 
Advanced IBD Nurse’s enhanced knowledge ensures assessment of patients’ immediate needs, 
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skilled decision-making and care–planning, and access to the safety net of MDT care services when 
needed [393, 411, 417, 418]. Length of hospital stay may also be reduced by IBD nurse-led follow up, 
thereby improving patient satisfaction overall [260, 285, 412, 419].  Balancing the delivery of safe 
and effective care in addition to managing cost savings, whilst challenging, is enhanced by the 
expertise of the IBD nursing team [400]. Whilst the initial costs of employing an IBD nurse are 
recognised to be high, the overall savings are undisputed in centres that employ IBD nurses [400].   
 
5.3 The benefit of the IBD Nurse for patient health-related quality of life and self-care  
 
The burden of disease for patients with IBD extends beyond the costs associated with their clinical 
care, investigations and treatments [420].  IBD often causes considerable social encumbrance, 
mainly due to the bowel-related symptoms.  Despite more liberal attitudes towards, for example, 
sexual function, bowels remain taboo. Patients can find it extremely difficult to talk about and seek 
support for their problems, despite the negative impact symptoms may have on educational and 
career aspirations, and on relationships and social activity generally.  
 
Whether face to face or via the AL, the Advanced IBD Nurse acts as a valuable resource for patients 
enabling them to learn more about their disease, thus increasing confidence, subsequent disease 
management ability, and directly benefitting their overall quality of life [262, 421-424]. Advanced 
IBD Nurses can also provide ongoing support to family and carers who may be affected by the 
repercussions of the disease and therefore require information, support and advice to manage 
concerns on a daily basis [393]. 
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It is crucial for successful treatment that patients acquire insight into their disease, and understand 
the importance of adhering to the recommended maintenance treatment regime. Despite non-
adherence being a major risk factor for experiencing a relapse and increasing the risk of acute 
hospitalisation and surgery, both adult and paediatric patients often fail to adhere to long term 
prescribed medication [425-427]. The Advanced IBD Nurse has the knowledge required to sensitively 
discuss issues that may affect a patient’s compliance. This may mean regular contact for reassurance 
and guidance or encouraging the patient’s independence in managing their disease through a guided 
self-management programme with ongoing support as required [423]. 
 
5.4 The Advanced IBD Nurse and e-health 
Since publication of the first N-ECCO consensus statements [1], care delivery in IBD has evolved to 
incorporate greater use of self-management and e-health platforms, and IBD nurses play a 
significant role in the development of these services [313, 314, 428, 429]. E-health in IBD refers to 
self-managed interactive web-based disease monitoring tools developed to individualize treatment 
and optimize patients’ self-management, adherence, and quality of life. A number of telemedicine 
systems have been developed, often managed by IBD nurses. The growth in email and text message 
communication, led by the Advanced IBD Nurse, is both acceptable to patients and cost effective 
[430]. Telemedicine applications, such as teleconsulting and tele-education improve treatment 
adherence, quality of life, and disease knowledge. Structured or shared decision-making support for 
patients and caregivers via e-health platforms may lead to more effective and efficient patient 
decision making, decreased psychosocial distress, and, ultimately, improved outcomes [1, 418, 431]. 
The development of e-health platforms reflects the increase in roles, responsibilities and influence 
of IBD nurses, as services in IBD care have increased.  
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5.5 The Advanced IBD Nurse and Research 
N-ECCO Statement 5B  
The importance of conducting robust empirical nursing research has been recognised across Europe 
[EL3]. More nurse-led research in IBD is being undertaken and a variety of methodologies are being 
used to explore interventions, describe living with IBD and evaluate the care of patients with IBD 
[EL3]. Continuing IBD nurse-led research is essential, and is an important aspect of the Advanced IBD 
Nurse role   
 
Robust empirical research supports IBD nurses’ clinical practice and demonstrates the value of the 
Advanced IBD Nurse. Across Europe, greater support for research is now available locally via 
collaboration with clinical colleagues, and internationally via the growing N-ECCO Research Forum. 
Advanced IBD Nurses are increasingly undertaking original research within the field of IBD care using 
a variety of different methodologies. Examples of nurse-led research include studies describing living 
with IBD [432, 433], and evaluating care and choice of care of patients with IBD [89, 261, 434]. 
 
Advanced IBD nurses have also led on studies exploring the development of new patient assessment 
tools [34], a continence assessment tool [152], and several studies aiming to explore and understand 
fatigue [225, 435, 436]. A recent N-ECCO collaboration to identify research priorities will be used to 
influence ongoing IBD nursing research across Europe [437].  
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IBD is a complex chronic condition requiring expert nursing care and management within the context 
of the MDT. These updated consensus statements build upon the original document [1] to provide 
contemporary guidance at local, national and international levels of IBD nursing care. The 
statements are intended to inform, inspire, and improve the standards of IBD care, providing 
evidence for IBD nurses to move from fundamental to advanced care, and to encourage research by 
IBD nurses. The evidence underpinning these statements may assist in developing business cases to 
support appointment of IBD nurses in new and expanding IBD services and will also work as a base 
when creating educational programmes for IBD nurses. 
 
 
Acknowledgement: All of the consensus group members for their work and commitment in 
producing this document. The ECCO Secretariat, for their continued support, advice and guidance in 
every stage of the production of this 2nd consensus document. Marian O’Connor Consultant Nurse, 
St. Marks Hospital, Watford Road, Harrow, HA1 3UJ London, United Kingdom for acting as an 
independent reviewer of this document prior to publication (November 2017)  
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this consensus: 
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6. Conclusion 
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DISCLAIMER TEXT 
The ECCO Consensus Guidelines are based on an international consensus process. Any treatment 
decisions are a matter for the individual clinician and should not be based exclusively on the content 
of the ECCO Consensus Guidelines. The European Crohn’s and Colitis Organisation and/or any of its 
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staff members and/or any consensus contributor may not be held liable for any information 
published in good faith in an ECCO Consensus Guideline. 
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